Effect of Resveratrol on Treatment of Bleomycin-Induced Pulmonary Fibrosis in Rats
Effect of Resveratrol on Treatment of Bleomycin-Induced Pulmonary Fibrosis in Rats
复制标题
DOI：
10.1007/s10753-012-9491-0
复制
发表时间：
2012-10-01
期刊：
影响因子：
5.1
通讯作者：
Yildirim, Zeki
中科院分区：
文献类型：
--
作者：
Akgedik, Recep;Akgedik, Sukran;Yildirim, Zeki
白藜芦醇对博莱霉素性肺纤维化有预防作用，但在治疗该纤维化方面尚无研究。本研究探讨白藜芦醇在治疗博莱霉素性肺纤维化中的作用。纤维化组气管内注射博莱霉素2.5 mg/kg，对照组注射生理盐水。第一剂白藜芦醇在博莱霉素后14天给药，一直持续到处死。第29天取肺组织，用Aschft标准和羟脯氨酸含量评价肺组织纤维化程度。与对照组(1.02+/-0.61 mg/g和1.88+/-0.59 mg/g)相比，博莱霉素使肝纤维化评分(3.70+/-1.04)和羟脯氨酸水平(4.99+/-0.90 mg/g组织)分别升高。白藜芦醇可使上述指标分别降至3.16+/-1.58(P=0.0001)和3.08+/-0.73(P>；0.05)。博莱霉素组大鼠组织丙二醛水平(0.55+/-0.22nmol/mg蛋白)高于对照组(0.16+/-0.07；P=0.0001)，白藜芦醇可使其降至0.16+/-0.06(P=0.0001)。白藜芦醇使组织总抗氧化能力增加到0.041+/-0.008(P=0.001)，而博莱霉素使组织总抗氧化能力降低(0.055+/-0.012 mmoltrolox Equiv/mg蛋白，P=0.0001)。结论白藜芦醇在治疗博莱霉素性大鼠肺纤维化方面有一定的应用前景。然而，不同剂量的药物仍需进一步研究。
Resveratrol has a preventive potential on bleomycin-induced pulmonary fibrosis in prophylactic use; however, it was not studied in the treatment of the fibrosis. This study investigated the role of resveratrol on the treatment of bleomycin-induced pulmonary fibrosis. Intratracheal bleomycin (2.5 mg/kg) was given in fibrosis groups and saline in controls. First dose of resveratrol was given 14 days after bleomycin and continued until sacrifice. On 29th day, fibrosis in lung was estimated by Aschoft's criteria and hydroxyproline content. Bleomycine increased the fibrosis score (3.70 +/- 1.04) and hydroxyproline levels (4.99 +/- 0.90 mg/g tissue) as compared to control rats (1.02 +/- 0.61 and 1.88 +/- 0.59 mg/g), respectively. These were reduced to 3.16 +/- 1.58 (P = 0.0001) and 3.08 +/- 0.73 (P > 0.05), respectively, by resveratrol. Tissue malondialdehyde levels in the bleomycin-treated rats were higher (0.55 +/- 0.22 nmol/mg protein) than that of control rats (0.16 +/- 0.07; P = 0.0001) and this was reduced to 0.16 +/- 0.06 by resveratrol (P = 0.0001). Tissue total antioxidant capacity is reduced (0.027 +/- 0.01) by bleomycine administration when compared control rats (0.055 +/- 0.012 mmol Trolox Equiv/mg protein; P = 0.0001) and increased to 0.041 +/- 0.008 (P = 0.001) by resveratrol. We concluded that resveratrol has some promising potential on the treatment of bleomycin-induced pulmonary fibrosis in rats. However, different doses of the drug should be further studied.